HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Possible Trump FDA Commish Candidate Favors (Much) Lighter Touch

This article was originally published in The Rose Sheet

Executive Summary

Jim O'Neill, a Silicon Valley investment manager, would be an unusual choice to head FDA, not just because he isn’t a physician, but because he’s favored substantially reducing FDA's role in assessing product effectiveness. While some experts are highly skeptical about O'Neill, who worked at HHS in the Bush administration, others suggest he could champion much-needed change at the agency.

Advertisement

Related Content

FDA Commish Nominee Could Be Mixed Blessing For Cosmetics Industry
Trump Meets With Two FDA Commissioner Candidates; Third Still In Play
Will US FDA Wind Up With More Political Positions Under Trump?
The Evolution Of 21st Century Cures Legislation
FDA, 23andMe Open Up Market Pathway For DTC Genetics

Topics

Advertisement
UsernamePublicRestriction

Register

RS108962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel